(Q43031370)

English

Accurate model predicting sustained response at week 4 of therapy with pegylated interferon with ribavirin in patients with chronic hepatitis C.

scientific article published in October 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Accurate model predicting sustained response at week 4 of therapy with pegylated interferon with ribavirin in patients with chronic hepatitis C. (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

1 reference

based on heuristic

inferred from title

pegylated interferon

1 reference

based on heuristic

inferred from title

Patrick Marcellin

10

object named as

Patrick Marcellin

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

author name string

M Martinot-Peignoux

1

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

L Comanor

2

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

J M Minor

3

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

M P Ripault

4

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

B-N Pham

5

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

N Boyer

6

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

C Castelnau

7

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

N Giuily

8

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

D Hendricks

9

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

publication date

1 October 2006

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Journal of Viral Hepatitis

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

13

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

701-707

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00750.X

21 January 2018

Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00750.X

21 January 2018

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00750.X

21 January 2018

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00750.X

21 January 2018

Monitoring of viral levels during therapy of hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00750.X

21 January 2018

Treatment of hepatitis C. The 2002 French consensus

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00750.X

21 January 2018

Multicenter evaluation of the performance characteristics of the bayer VERSANT HCV RNA 3.0 assay (bDNA)

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00750.X

21 January 2018

An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00750.X

21 January 2018

Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00750.X

21 January 2018

Predictors of sustained response to alpha interferon therapy in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00750.X

21 January 2018

Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00750.X

21 January 2018

Lack of benefit of escalating dosage of interferon alfa in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00750.X

21 January 2018

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00750.X

21 January 2018

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00750.X

21 January 2018

Identifiers

10.1111/J.1365-2893.2006.00750.X

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

release_tqectrfiwrcsljnxjozascxfeq

1 reference

https://api.fatcat.wiki/v0/release/tqectrfiwrcsljnxjozascxfeq

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43031370&oldid=1837828637"